Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Adynamic Bone Disease
- Cardiac Disease
- Chronic Kidney Disease Mineral and Bone Disorder
- Chronic Kidney Diseases
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 120 years
- Gender
- Both males and females
Description
This study is a 1:1 randomized controlled trial with an intervention for 18 months and a follow up period of 12 months. The study will explore if treatment with recombinant human parathyroid hormone (PTH) improves bone turnover and bone mineral density (BMD), and thereby prevents the high risk of fr...
This study is a 1:1 randomized controlled trial with an intervention for 18 months and a follow up period of 12 months. The study will explore if treatment with recombinant human parathyroid hormone (PTH) improves bone turnover and bone mineral density (BMD), and thereby prevents the high risk of fracture in patients with chronic kidney disease (CKD). Disturbed bone metabolism is related to increased risk of cardiovascular disease in patients with CKD. This study also wishes to examine of treatment with recombinant PTH improves cardiovascular parameters.
Tracking Information
- NCT #
- NCT04522622
- Collaborators
- Odense University Hospital
- Steno Diabetes Center Copenhagen
- Rigshospitalet, Denmark
- Universiteit Antwerpen
- Investigators
- Principal Investigator: Ditte Hansen, MD, PhD Department of Nephrology, Herlev and Gentofte Hospital
Get Well Soon